WallStSmart

argenx NV ADR (ARGX)vsPrecision BioSciences Inc (DTIL)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

argenx NV ADR generates 13033% more annual revenue ($5.92B vs $45.04M). ARGX leads profitability with a 31.7% profit margin vs -85.6%. DTIL trades at a lower P/E of 30.3x. ARGX earns a higher WallStSmart Score of 73/100 (B).

ARGX

Strong Buy

73

out of 100

Grade: B

Growth: 10.0Profit: 9.5Value: 6.7Quality: 6.0
Piotroski: 3/9Altman Z: 4.92

DTIL

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.5
Piotroski: 2/9Altman Z: -3.79
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ARGXUndervalued (+67.3%)

Margin of Safety

+67.3%

Fair Value

$2552.01

Current Price

$950.95

$1601.06 discount

UndervaluedFair: $2552.01Overvalued
DTILUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$9.38

Current Price

$7.28

$2.10 discount

UndervaluedFair: $9.38Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ARGX6 strengths · Avg: 10.0/10
Return on EquityProfitability
32.8%10/10

Every $100 of equity generates 33 in profit

Profit MarginProfitability
31.7%10/10

Keeps 32 of every $100 in revenue as profit

Operating MarginProfitability
36.3%10/10

Strong operational efficiency at 36.3%

Revenue GrowthGrowth
52.1%10/10

Revenue surging 52.1% year-over-year

EPS GrowthGrowth
50.6%10/10

Earnings expanding 50.6% YoY

Altman Z-ScoreHealth
4.9210/10

Safe zone — low bankruptcy risk

DTIL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37272.0%10/10

Revenue surging 37272.0% year-over-year

Areas to Watch

ARGX3 concerns · Avg: 3.0/10
P/E RatioValuation
32.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Price/BookValuation
176.8x2/10

Trading at 176.8x book value

DTIL4 concerns · Avg: 3.5/10
P/E RatioValuation
30.3x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ARGX

The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.

Bull Case : DTIL

The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.

Bear Case : ARGX

The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.

Bear Case : DTIL

The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.

Key Dynamics to Monitor

ARGX profiles as a growth stock while DTIL is a hypergrowth play — different risk/reward profiles.

DTIL carries more volatility with a beta of 1.35 — expect wider price swings.

DTIL is growing revenue faster at 37272.0% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ARGX scores higher overall (73/100 vs 26/100), backed by strong 31.7% margins and 52.1% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

argenx NV ADR

HEALTHCARE · BIOTECHNOLOGY · USA

argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.

Precision BioSciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

Visit Website →

Want to dig deeper into these stocks?